Other Events ·
Mereo BioPharma Group plc received a second notice from Nasdaq indicating it has not yet regained compliance with the…
MREOMereo BioPharma Group plc
Mereo BioPharma Group plc received a second notice from Nasdaq indicating it has not yet regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The company was granted an additional 180-day compliance period, extending until February 16, 2027, to restore its stock price above the threshold. If Mereo fails to meet this requirement by the end of the second compliance period, its securities will be subject to delisting, though it retains the right to appeal such a determination to a Nasdaq Hearings Panel. The filing notes that these notices have no immediate effect on the current listing status and management intends to monitor the closing bid price while considering available options to regain compliance. Mereo BioPharma Group plc operates in the biotechnology industry, focusing on the development of therapies for rare diseases.